<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03409380</url>
  </required_header>
  <id_info>
    <org_study_id>FWA 00006218</org_study_id>
    <nct_id>NCT03409380</nct_id>
  </id_info>
  <brief_title>Supplementation Trial on Arginine With Metabolic Profiling</brief_title>
  <acronym>STAMP</acronym>
  <official_title>Supplementation Trial on Arginine With Metabolic Profiling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pennington Biomedical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jennifer C. Rood</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Robbie A. Beyl</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Corby K. Martin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Frank L. Greenway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pennington Biomedical Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess effects of an acute dose of the amino acid arginine on metabolism in
      healthy young men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double - blind randomized, crossover design trial examining arginine vs. placebo beverage
      treatments will be performed. The primary objective is to determine the effects of arginine
      assessed by standard laboratory assays and metabolomics. To accomplish the objective
      standardized meals will be provided for 2 days preceding treatment for dietary consistency.
      Participants will arrive at the center following a 10-12 hr fast. Blood samples will be
      collected at baseline (fasting), 1.5 hrs, 3.0 hrs, 6.0 hrs, and 24 hrs post treatment. Plasma
      prolactin, growth hormone, amino acids, glucose, insulin, triacylglycerols, thyroid hormones
      (TSH, T3, and T4), sex hormone binding globulin (SHBH), testosterone, cortisol, DHEA, and
      citrulline will be measured. Metabolomics will be measured at 3 time points for each
      treatment. Peripheral arterial tonometry (PAT) will also be performed at ~2 hrs following
      treatment to examine endothelial function in response to nitrous oxide release. In addition,
      psychological status including fatigue will be assessed using a standardized mood
      questionnaire (POMS).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2018</start_date>
  <completion_date type="Anticipated">December 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>double - blind randomized, crossover design trial</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Growth Hormone</measure>
    <time_frame>baseline (fasting), 1.5, 3.0, 6.0, and 24.0 hrs</time_frame>
    <description>Change in GH</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Protein</condition>
  <condition>Amino Acid</condition>
  <condition>Arginine</condition>
  <arm_group>
    <arm_group_label>Arginine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arginine drink provided 1 time. There is about 10 g of arginine in the product.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo drink provided 1 time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Arginine Drink</intervention_name>
    <description>10 g of arginine in a formulated drink</description>
    <arm_group_label>Arginine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Plain Drink</intervention_name>
    <description>formulated drink</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 18.5 - 25 kg/m2.

          -  Must be physically active (exercise at least 2 days/week).

          -  Willing to refrain from alcohol and supplements for the duration of the study.

          -  Willing to refrain from supplement ingestion, nuts, watermelon, and cracklins
             (fatback) for the 2 weeks prior to the initial treatment diet through the duration of
             the study.

        Exclusion Criteria:

          -  HIV or AIDS

          -  Uncontrolled CVD/arrhythmia

          -  Type I or type II diabetes

          -  Pregnancy (or breastfeeding)

          -  Diagnosed eating disorder

          -  Non-normal sleeping patterns

          -  Chronic neurological condition

          -  Altered metabolism including growth hormone disorders

          -  Use of nicotine or tobacco products

          -  Heavy caffeine use (â‰¥ 350 mg caffeine/d)

          -  Whole blood donation within previous eight weeks

          -  Protein supplementation

          -  Protein wasting disease.

          -  Exclusionary medications include diuretics, beta-blockers, weight loss medications or
             diet pills, anti-inflammatory drugs (corticosteroid/ anabolic steroid/NSAID),
             antipsychotic medication or other medication that may affect fluid balance,
             metabolism, or body weight.

          -  Prisoners and adults who are unable to consent will be excluded from the study.

          -  Lastly any other medical, psychiatric, or behavioral factors in the judgement of the
             Principle Investigator that may interfere with study participation or the ability to
             follow the protocol.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John W Apolzan, PhD</last_name>
      <phone>225-763-2827</phone>
      <email>john.apolzan@pbrc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pennington Biomedical Research Center</investigator_affiliation>
    <investigator_full_name>John Apolzan</investigator_full_name>
    <investigator_title>Asst Professor</investigator_title>
  </responsible_party>
  <keyword>growth hormone</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

